NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Remember this interview with Linda F. Powers?

Highlights:

Q: What attracted you to Northwest Biotherapeutics?

Ms. Powers: What attracted me to Northwest Biotherapeutics was that they have a platform technology that should be applicable to pretty much all cancers, and which is offering really a major improvement in survival times for patients, with no toxicity . . . .

Ms. Powers: We are entering the home stretch now. . . It is the operational aspect of completing the clinical trial, which is a huge managerial task with a lot of moving parts. There are also a lot of issues in regard to the market strategy, the pricing strategy, the reimbursement strategy and the manufacturing.

Q: Why should potential investors pay attention to Northwest Biotherapeutics?

Ms. Powers: Biotech investments are high-risk/high-return investments. However, Northwest Biotherapeutics has survived, produced strong results and gotten to such a late stage in the process, where we have greatly reduced the risk: “de-risking” as the investor community likes to call it. In addition to the de-risking, investors can still have the upside as the market cap of Northwest is still very low.

Northwest has now reached the stage where it has consistent, strikingly positive results across multiple different cancers, and across many years, with a decade
worth of clinical trials. Yet, as just mentioned, Northwest’s market cap has not yet gone through its inflection, so the whole upside is still there. That is the kind of combination of circumstances that is well worth looking at for an investor.

Q: Final thoughts, what should people remember most about Northwest Biotherapeutics?

Ms. Powers: I would just refer your readers as a comparison to look at the inflection, the value run-up that Dendreon went through when it reached the end of its late-stage clinical trial and had a successful outcome of that trial. They went from a market cap of $300 million to a market cap of $5 billion and that is an amazing upside potential. . . . so stay tuned!


http://www.ceocfointerviews.com/interviews/NWBO-NorthwestBio11-CEOCFO-Article.pdf